Refusal of orphan designation for treatment of eumycetoma

benzyl benzoate / beta-caryophyllene / cineole / cinnamaldehyde / cinnamyl acetate / linalool / trans-2-methoxycinnamaldehyde
OrphanHuman

Overview

On 18 June 2020, the Committee for Orphan Medicinal Products (COMP) adopted a negative opinion on the orphan designation application for benzyl benzoate, beta-caryophyllene, cineole, cinnamaldehyde, cinnamyl acetate, linalool, trans-2-methoxycinnamaldehyde for the treatment of eumycetoma. A negative decision C(2020) 5580 was issued by the European Commission on 10 August 2020.

The sponsor applied for orphan designation on the basis of the seriousness and the rarity of the condition, as well as an assumption of potential benefit over currently available methods of treatment.

The negative opinion was based on the following reasons(s):

  • The sponsor failed to demonstrate that the medicine would provide a significant benefit to patients with eumycetoma over currently available methods of treatment. Although results from laboratory studies suggest that the medicine would provide marginal improvement in survival compared with itraconazole (standard treatment for eumycetoma), it is not clear whether these improvements would be meaningful to patients. In addition, significant benefit over other authorised treatments for eumycetoma has not been established.

Requests for designation as an orphan medicinal product are made for investigational products. Absence of orphan designation does not preclude the development of this product, including its use in clinical trials. A marketing authorisation can still be obtained if quality, safety and efficacy are demonstrated.

Public summary of opinion on orphan designation: Benzyl benzoate, beta-caryophyllene, cineole, cinnamaldehyde, cinnamyl acetate, linalool, trans-2-methoxycinnamaldehyde for the treatment of eumycetoma

Adopted Reference Number: EMADOC-628903358-2613

English (EN) (156.44 KB - PDF)

First published:
View

Key facts

Active substance
  • benzyl benzoate
  • beta-caryophyllene
  • cineole
  • cinnamaldehyde
  • cinnamyl acetate
  • linalool
  • trans-2-methoxycinnamaldehyde
Intended use
Treatment of eumycetoma
Orphan designation status
Negative
EU designation number
-
Date of refusal of designation
Sponsor

Septeos S.A.S.
12 Avenue De La Grande Armee
75017 Paris
France

EMA list of opinions on orphan medicinal product designation

EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Share this page